Comparison of Abbott ID NOW COVID-19 Rapid Molecular Assay to Allplex 2019-nCoV and VIASURE SARS-CoV-2 Detection in Nasal Swabs
Keywords:ID NOW, COVID-19, Allplex, VIASURE, SARS-CoV-2
BACKGROUND: Readily available, accurate, and rapid diagnostic technologies are of high priority to contain emerging and re-emerging pandemics and to properly allocate personal protective equipment usage and preventing nosocomial spread with subsequent community transmission. Detection of positive 2019-nCoV nucleic acids by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR)-based assays remains the gold standard for COVID-19 diagnostics. However, these assays take an average over 3–5 h to generate results and the PCR tests require certified laboratories, expensive equipment, and trained technicians to operate. Therefore, there is an urgent need for rapid point of care molecular tests that can be readily used in a healthcare setting that generates reliable results within few hours. Those tests should provide reliable results in the setting to facilitate the diagnosis and rapid decision-making.
AIM: The present study aimed to evaluate the diagnostic performance of Abbott ID NOW SARS-CoV-2 compared to two gold standard assays (Allplex 2019- nCoV and VIASURE SARS-CoV-2) and to detect the relation between viral load and the sensitivity of ID NOW SARS-CoV-2 assay.
METHODS: A total of 86 and 42 nasopharyngeal swabs collected from patients attending the Reference Laboratory of Egyptian University Hospitals during the period from January 2022 to May 2022, were tested by our reference methods of RT-PCR for COVID-19 detection; VIASURE kit and Allplex kits, respectively. Corresponding dry nasal swabs were collected from the same patients for ID NOW SARS-CoV-2 ribonucleic acid (RNA) detection assay.
RESULTS: As regards the results of the 86 nasopharyngeal swabs tested by both VIASURE kit and ID NOW, there was a good agreement between both methods (95%) (kappa = 0.924), where the ID NOW method was not able to detect three COVID-19-positive samples (3/86, 5.1%). ID NOW exhibited specificity and sensitivity of 100% and 94.9%, respectively. As for comparing results of ID NOW with Allplex kit, the results of the 42 nasopharyngeal swabs tested by both tests revealed good agreement between both methods (kappa = 0.908). In comparison with Allplex kit, ID NOW exhibited specificity and sensitivity of 90% and 100%, respectively. Regarding the relation between the viral load detected by VIASURE kit and results of the ID NOW test, we found that ID NOW showed a sensitivity of 82.35% in samples with low viral load (CT > 30), while for samples with intermediate (CT: 20–30) and high (CT < 20) viral loads, sensitivity was 100%.CONCLUSION: ID NOW assay in our study exhibited a high diagnostic performance when evaluated with the gold standard RT-PCR methods. Our study further substantiates the high sensitivity of ID NOW in the presence of intermediate and high viral loads detected by molecular RT-PCR SARS-CoV-2 testing. Its analytical performances, combined with the very short 13 min reactional time and the friendly device-guided handling procedure, constitute an additional advantage of ID NOW COVID-19 for setting up a rapid diagnosis within the clinical laboratories and for timely identification of outbreaks allowing for aggressive contact tracing and containment.
Plum Analytics Artifact Widget Block
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382:727-33. https://doi.org/10.1056/NEJMoa2001017 PMid:31978945 DOI: https://doi.org/10.1056/NEJMoa2001017
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-9. https://doi.org/10.1038/s41586-020-2008-3 PMid:32015508 DOI: https://doi.org/10.1038/s41586-020-2008-3
Gorbalenya AE, Baker SC, Baric RS, De Groot RJ, Drosten C, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group. bioRXiv. 2020;9:8. https://doi.org/10.1101/2020.02.07.937862 DOI: https://doi.org/10.1101/2020.02.07.937862
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva, Switzerland: WHO; 2020.
World Health Organization. Coronavirus Disease (COVID-19) Pandemic. Geneva, Switzerland: World Health Organization; 2020. Available from: https://www.who.int/emergencies/ diseases/novel-coronavirus2019 [Last accessed on 2020 Dec 01].
Egypt’s Health Ministry. 14 February 2020. Egypt Announces First Coronavirus Infection. Archived from the Original on 15 February, 2020.
Egypt’s Health Ministry Daily Reports. Outbreak of COVID-19 Infection in Egypt.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507-13. https://doi.org/10.1016/S0140-6736(20)30211-7 PMid:32007143 DOI: https://doi.org/10.1016/S0140-6736(20)30211-7
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565-74. PMid:32007145 DOI: https://doi.org/10.1016/S0140-6736(20)30251-8
Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254. https://doi.org/10.3390/v12030254 Mid:32106567 DOI: https://doi.org/10.3390/v12030254
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Cureus. 2020;12(3):e7423. https://doi.org/10.7759/cureus.7423 PMid:32337143 DOI: https://doi.org/10.7759/cureus.7423
Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11:59. https://doi.org/10.3390/v11010059 PMid:30646565 DOI: https://doi.org/10.3390/v11010059
Plebani M, Laposata M, Lippi G. A manifesto for the future of laboratory medicine professionals. Clin Chim Acta. 2019;489:49-52. https://doi.org/10.1016/j.cca.2018.11.021 PMid:30445032 DOI: https://doi.org/10.1016/j.cca.2018.11.021
Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of nucleocapsid and spike protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58:e00461-20. https://doi.org/10.1128/JCM.00461-20 PMid:32229605 DOI: https://doi.org/10.1101/2020.03.16.20035014
Zhao JY, Yan JY, Qu JM. Interpretations of “diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7)”. Chin Med J Engl. 2020;133:1347-49. https://doi.org/10.1097/CM9.0000000000000866 PMid:32301757 DOI: https://doi.org/10.1097/CM9.0000000000000866
Zhang J, Zahn M, Yousaf A, Xie A. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861-8. https://doi.org/10.1038/s41591-020-0877-5 PMid:32327757 DOI: https://doi.org/10.1038/s41591-020-0877-5
Robert K, Arkadiusz D. Molecular and serological tests for COVID-19 a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel). 2020;10(6):434. https://doi.org/10.3390/diagnostics10060434 PMid:32604919 DOI: https://doi.org/10.3390/diagnostics10060434
Farfour E, Lesprit P, Visseaux B, Pascreau T, Jolly E, Houhou N, et al. The Allplex 2019-nCoV (Seegene) assay: Which performances are for SARS-CoV-2 infection diagnosis? Eur J Clin Microbiol Infect Dis. 2020;39(10):1997-2000. https://doi.org/10.1007/s10096-020-03930-8 PMid:32462501 DOI: https://doi.org/10.1007/s10096-020-03930-8
Harrington A, Cox B, Snowdon J, Bakst J, Ley E, Grajales P, et al. Comparison of Abbott ID-NOW and Abbott m2000 Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients. J Clin Microbiol. 2020;58(8):e00798-20. https://doi.org/10.1128/JCM.00798-20 PMid:32327448 DOI: https://doi.org/10.1128/JCM.00798-20
Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, et al. Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City academic institution. J Clin Microbiol. 2020;58(8):e01136-20. https://doi.org/10.1128/JCM.01136-20 PMid:32471894 DOI: https://doi.org/10.1128/JCM.01136-20
Freire B, Vega P, Velez A, Castillo P, Cruz M, Perezet F, et al. Evaluation of VIASURE SARS-CoV-2 RT-qPCR kit (CerTest Biotec) using CDC FDA EUA RT-qPCR kit as a gold standard. MedRvix. 2020; 2021;553:154-6. https://doi.org/10.1016/j.virol.2020.10.010
Freppel W, Merindol N, Rallu F, Bergevinet M. Efficient SARS-CoV-2 detection in unextracted oro-nasopharyngeal specimens by rRT-PCR with the Seegene Allplex™ 2019-nCoV assay. Virol J. 2020;17(1):196. https://doi.org/10.1186/s12985-020-01468-x PMid:33339539 DOI: https://doi.org/10.1186/s12985-020-01468-x
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249-51. https://doi.org/10.1001/jama.2020.8259 PMid:32374370 DOI: https://doi.org/10.1001/jama.2020.8259
Freire B, Vega P, Velez A, Cruz M, Perez F, Angel M. Analytical and clinical comparison of VIASURE (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis. Virology. 2021;553:154-6. https://doi.org/10.1016/j.virol.2020.10.010 PMid:33278737 DOI: https://doi.org/10.1016/j.virol.2020.10.010
Bogiel T, Rzepka M, Depka D. Reliable diagnostics of SARS-CoV-2 infections using one- and two-gene molecular tests for a viral RNA detection-results questioning previous observations. Diagnostics. 2021;11(10):1839. https://doi.org/10.3390/diagnostics11101839 PMid:34679537 DOI: https://doi.org/10.3390/diagnostics11101839
Mitchell S, George K. Evaluation of the COVID19 ID-NOW EUA assay. J Clin Virol. 2020;128:104429. https://doi.org/10.1016/j.jcv.2020.104429 PMid:32425657 DOI: https://doi.org/10.1016/j.jcv.2020.104429
Sepulveda J, Abdulbaki R, Sands Z, Codoy M, Mendoza S, Isaacson N, et al. Performance of the Abbott ID-NOW rapid SARS-CoV-2 amplification assay in relation to nasopharyngeal viral RNA loads. J Clin Virol. 2021;140:104843. https://doi.org/10.1016/j.jcv.2021.104843 PMid:33979738 DOI: https://doi.org/10.1016/j.jcv.2021.104843
Green D, Zucker J, Westblade L, Whittier S, Rennert H, Velu P, et al. Clinical performance of SARS-CoV-2 molecular tests. J Clin Microbiol. 2020;58(8):e00995-20. https://doi.org/10.1128/JCM.00995-20 PMid:32513858 DOI: https://doi.org/10.1128/JCM.00995-20
Ridgway JP, Pisano J, Landon E, Beavis KG, Robicsek A. Clinical sensitivity of severe acute respiratory syndrome coronavirus 2 nucleic acid amplification tests for diagnosing coronavirus disease 2019. Open Forum Infect Dis. 2020;7(8):ofaa315. https://doi.org/10.1093/ofid/ofaa315 PMid:32818146 DOI: https://doi.org/10.1093/ofid/ofaa315
Kawasuji H, Takegoshi Y, Kaneda M, Ueno A, Miyajima Y, Kawago K, et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS One. 2020;15(12):e0243597. https://doi.org/10.1371/journal.pone.0243597 PMid:33296437 DOI: https://doi.org/10.1371/journal.pone.0243597
Soria M, Cortón M, Martínez B, Lobo R, Vázquez L, López R, et al. High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease. Access Microbiol. 2021;21;3(9):000259. https://doi.org/10.1099/acmi.0.000259 PMid:34712904 DOI: https://doi.org/10.1099/acmi.0.000259
Ramachandran A, Noble J, Deucher A, Miller S, Tang P, Wang R. Performance of Abbott ID-Now rapid nucleic amplification test for laboratory identification of COVID-19 in asymptomatic emergency department patients. J Am Coll Emerg Physicians Open. 2021;2(6):e12592. https://doi.org/10.1002/emp2.12592 PMid:35005704 DOI: https://doi.org/10.1002/emp2.12592
Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465-9. https://doi.org/10.1038/s41586-020-2196-x PMid:32235945 DOI: https://doi.org/10.1038/s41586-020-2196-x
Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020;71(10):2663-6. https://doi.org/10.1093/cid/ciaa638 PMid:32442256 DOI: https://doi.org/10.1093/cid/ciaa638
Scola BL, Bideau ML, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059-61. https://doi.org/10.1007/s10096-020-03913-9 PMid:32342252 DOI: https://doi.org/10.1007/s10096-020-03913-9
Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair AA, Alhumaid S, et al. Dynamics and real-time RT-PCR Ct values correlation with disease severity in COVID-19. Diagnostics. 2021;11:1091. https://doi.org/10.3390/diagnostics11061091 PMid:34203738 DOI: https://doi.org/10.3390/diagnostics11061091
How to Cite
Copyright (c) 2022 Ghada Ismail, Dalia Abdelhamid, Rania Abdelhalim, Marwa Salah Mostafa, Hossam Abdelghaffar, Noha Alaa Eldin Fahim, Ahmed Elshafei, Nashwa Naguib (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.